About Advanced Accelerator Applications
Advanced Accelerator Applications is a Healthcare company based in Saint-genis-pouilly (France) founded in 2002, and was acquired by Novartis in October 2017. Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. Advanced Accelerator Applications has raised $56.13 million across 2 funding rounds from investors including Novartis and HBM Partners. Advanced Accelerator Applications has completed 3 acquisitions, including Atreus Pharmaceuticals, IDB Holland and PET Net. Advanced Accelerator Applications offers products and services including Radioligand Therapies and Radionuclide Molecular Imaging. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Founded in 2002 as a spin-off from CERN in Geneva, Switzerland, Advanced Accelerator Applications operates in the nuclear medicine sector. Radiopharmaceuticals for PET and SPECT imaging in oncology, neurology, cardiology, and infectious diseases are developed, manufactured, and commercialized. The company, acquired by Novartis in 2017, is headquartered in Saint-Genis-Pouilly, France, with Lutathera approved by the FDA for treating certain neuroendocrine tumors.
- Headquarters Saint-genis-pouilly, France
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website adacap.com
- Social LinkedIn
- Acquired by Novartis (Oct 2017)
- Legal Name Advanced Accelerator Applications
- Annual Revenue$235.08 M (USD)48as on Dec 31, 2023
- Net Profit$43.24 M (USD)21as on Dec 31, 2023
- EBITDA$43.24 M (USD)21as on Dec 31, 2023
- Total Equity Funding$56.13M (USD)
in 2 rounds
- Latest Funding Round$283.07K (USD), Grant
Apr 2015
- InvestorsNovartis
& 1 more
- Investments & AcquisitionsAtreus Pharmaceuticals
& 2 more
- Acquired byNovartis
(Oct 2017)
Products & Services of Advanced Accelerator Applications
Advanced Accelerator Applications offers a comprehensive portfolio of products and services, including Radioligand Therapies and Radionuclide Molecular Imaging.
Targeted therapies using radioactive ligands to treat tumors effectively.
Imaging solutions for detecting and monitoring cancer progression.
Funding Insights of Advanced Accelerator Applications
Advanced Accelerator Applications has successfully raised a total of $56.13M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $283.07 thousand completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56.13M
- Total Rounds 2
- Last Round Grant — $283,075
- First Round $56.13M
(Feb 2014)
- Investors Count 1
All 2 funding rounds of Advanced Accelerator Applications with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2015 | $283,075 | Grant | – | – | – |
| Feb 2014 | $56.13M | Series B | – | – |
2 investors in total: 2 institutional.
Investors in Advanced Accelerator Applications
Advanced Accelerator Applications has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis and HBM Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Advanced Accelerator Applications
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Advanced Accelerator Applications
1 people are tracked at Advanced Accelerator Applications (1 in leadership).
| Name | Role | Group |
|---|---|---|
Caio Kugelmas | Chief Growth Officer | Leadership |
Complete people profiles for Advanced Accelerator Applications
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Advanced Accelerator Applications
Advanced Accelerator Applications has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Atreus Pharmaceuticals, IDB Holland and PET Net.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Radiopharmaceuticals are manufactured by PET Net in Germany. | petnet-gmbh.de | Erlangen, Germany | 1998 | Jun 2016 | •••• | |
Radiopharmaceutical devices are manufactured in the Netherlands. | idb-holland.com | Baarle Nassau, Netherlands | 2016 | Jan 2016 | •••• | |
In vivo imaging diagnostics for autoimmune diseases are developed. | atreuspharma.com | Ottawa, Canada | 2007 | Jan 2015 | •••• |
Complete acquisition details for Advanced Accelerator Applications
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Advanced Accelerator Applications
8 dated milestones of Advanced Accelerator Applications across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Advanced Accelerator Applications is founded.
- Funding First funding round of $56.1M.
- Acquisition Acquires Atreus Pharmaceuticals.
- Funding Latest funding round, Grant, of $283K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires IDB Holland.
- Acquisition Acquires PET Net.
- Exit Acquired by Novartis.
Web traffic of Advanced Accelerator Applications
The website of Advanced Accelerator Applications (adacap.com) receives about 8.5K visits a month and ranks #2,780,200 among all websites worldwide, #3,742 in Biotechnology and Pharmaceuticals.
- Monthly visits8.5K
▲ 21.1% vs previous month
- Unique visitors2.8K
per month
- Global rank#2,780,200
among all websites
- Category rank#3,742
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.0
- Average visit34 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with Advanced Accelerator Applications. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
otosan.com | otosan.com | 100% | #1,239,872 | – | |
fuesmen.edu.ar | fuesmen.edu.ar | 72% | #477,123 | – | |
interactive.snm.org | interactive.snm.org | 72% | – | ||
leem.org | leem.org | 72% | #480,709 | – | |
pharmaceutiques.com | pharmaceutiques.com | 72% | #5,843,762 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Advanced Accelerator Applications
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Advanced Accelerator Applications
Complete news archive for Advanced Accelerator Applications
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Advanced Accelerator Applications
Advanced Accelerator Applications was founded in 2002 and raised its 1st funding round 12 years after it was founded.
Advanced Accelerator Applications is headquartered in Saint-genis-pouilly, France. It is registered at Saint-genis-pouilly, Ain, France.
Advanced Accelerator Applications is a funded company, having raised a total of $56.13M across 2 funding rounds to date. The company's 1st funding round was a Series B of $56.13M, raised on Feb 2014.
Annual revenue of Advanced Accelerator Applications is $235.08M as on Dec 31, 2023.
Founded in 2002 as a spin-off from CERN in Geneva, Switzerland, Advanced Accelerator Applications operates in the nuclear medicine sector. Radiopharmaceuticals for PET and SPECT imaging in oncology, neurology, cardiology, and infectious diseases are developed, manufactured, and commercialized. The company, acquired by Novartis in 2017, is headquartered in Saint-Genis-Pouilly, France, with Lutathera approved by the FDA for treating certain neuroendocrine tumors.
Advanced Accelerator Applications offers Radioligand Therapies and Radionuclide Molecular Imaging.
Advanced Accelerator Applications has made 3 acquisitions, including Atreus Pharmaceuticals, IDB Holland, and PET Net.
Advanced Accelerator Applications has 2 investors. Key investors include Novartis, and HBM Partners.
Advanced Accelerator Applications operates through Advanced Accelerator Applications.
Yes. Advanced Accelerator Applications was acquired by Novartis in October 2017.